Literature DB >> 30110637

Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.

Natalia A Kuzmina1, Patrick Younan1, Pavlo Gilchuk2, Rodrigo I Santos1, Andrew I Flyak3, Philipp A Ilinykh1, Kai Huang1, Ndongala M Lubaki1, Palaniappan Ramanathan1, James E Crowe4, Alexander Bukreyev5.   

Abstract

Some monoclonal antibodies (mAbs) recovered from survivors of filovirus infections can protect against infection. It is currently unknown whether natural infection also induces some antibodies with the capacity for antibody-dependent enhancement (ADE). A panel of mAbs obtained from human survivors of filovirus infection caused by Ebola, Bundibugyo, or Marburg viruses was evaluated for their ability to facilitate ADE. ADE was observed readily with all mAbs examined at sub-neutralizing concentrations, and this effect was not restricted to mAbs with a particular epitope specificity, neutralizing capacity, or subclass. Blocking of specific Fcγ receptors reduced but did not abolish ADE that was associated with high-affinity binding antibodies, suggesting that lower-affinity interactions still cause ADE. Mutations of Fc fragments of an mAb that altered its interaction with Fc receptors rendered the antibody partially protective in vivo at a low dose, suggesting that ADE counteracts antibody-mediated protection and facilitates dissemination of filovirus infections.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ebola virus; FC receptor; antibody; enhancement of infection; epitope; filovirus

Mesh:

Substances:

Year:  2018        PMID: 30110637      PMCID: PMC6697154          DOI: 10.1016/j.celrep.2018.07.035

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  81 in total

Review 1.  N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.

Authors:  Fabian Higel; Andreas Seidl; Fritz Sörgel; Wolfgang Friess
Journal:  Eur J Pharm Biopharm       Date:  2016-01-13       Impact factor: 5.571

2.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection.

Authors:  Kobporn Boonnak; Kaitlyn M Dambach; Gina C Donofrio; Boonrat Tassaneetrithep; Mary A Marovich
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

4.  Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies.

Authors:  Xiangguo Qiu; Judie B Alimonti; P Leno Melito; Lisa Fernando; Ute Ströher; Steven M Jones
Journal:  Clin Immunol       Date:  2011-08-31       Impact factor: 3.969

5.  Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Authors:  Chad E Mire; Joan B Geisbert; Viktoriya Borisevich; Karla A Fenton; Krystle N Agans; Andrew I Flyak; Daniel J Deer; Herta Steinkellner; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Andrew Hiatt; Do H Kim; Michael H Pauly; Jesus Velasco; Kevin J Whaley; James E Crowe; Larry Zeitlin; Thomas W Geisbert
Journal:  Sci Transl Med       Date:  2017-04-05       Impact factor: 17.956

6.  Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.

Authors:  N M Kudoyarova-Zubavichene; N N Sergeyev; A A Chepurnov; S V Netesov
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

7.  Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.

Authors:  Ririn Ramadhany; Itaru Hirai; Tadahiro Sasaki; Ken-ichiro Ono; Pongrama Ramasoota; Kazuyoshi Ikuta; Takeshi Kurosu
Journal:  Antiviral Res       Date:  2015-10-30       Impact factor: 5.970

8.  Fcγ-receptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection.

Authors:  Wakako Furuyama; Andrea Marzi; Aaron B Carmody; Junki Maruyama; Makoto Kuroda; Hiroko Miyamoto; Asuka Nanbo; Rashid Manzoor; Reiko Yoshida; Manabu Igarashi; Heinz Feldmann; Ayato Takada
Journal:  PLoS Pathog       Date:  2016-12-30       Impact factor: 6.823

9.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

10.  Modelling Virus and Antibody Dynamics during Dengue Virus Infection Suggests a Role for Antibody in Virus Clearance.

Authors:  Hannah E Clapham; Than Ha Quyen; Duong Thi Hue Kien; Ilaria Dorigatti; Cameron P Simmons; Neil M Ferguson
Journal:  PLoS Comput Biol       Date:  2016-05-23       Impact factor: 4.475

View more
  27 in total

1.  Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.

Authors:  Philipp A Ilinykh; Kai Huang; Rodrigo I Santos; Pavlo Gilchuk; Bronwyn M Gunn; Marcus M Karim; Jenny Liang; Mallorie E Fouch; Edgar Davidson; Diptiben V Parekh; James B Kimble; Colette A Pietzsch; Michelle Meyer; Natalia A Kuzmina; Larry Zeitlin; Erica Ollmann Saphire; Galit Alter; James E Crowe; Alexander Bukreyev
Journal:  Cell Host Microbe       Date:  2020-04-21       Impact factor: 21.023

2.  Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein.

Authors:  Mark J Bailey; Felix Broecker; Alec W Freyn; Angela Choi; Julia A Brown; Nadia Fedorova; Viviana Simon; Jean K Lim; Matthew J Evans; Adolfo García-Sastre; Peter Palese; Gene S Tan
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

Review 3.  Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19.

Authors:  Yanghong Ni; Aqu Alu; Hong Lei; Yang Wang; Min Wu; Xiawei Wei
Journal:  Mol Biomed       Date:  2021-01-20

4.  Pan-ebolavirus protective therapy by two multifunctional human antibodies.

Authors:  Pavlo Gilchuk; Charles D Murin; Robert W Cross; Philipp A Ilinykh; Kai Huang; Natalia Kuzmina; Viktoriya Borisevich; Krystle N Agans; Joan B Geisbert; Seth J Zost; Rachel S Nargi; Rachel E Sutton; Naveenchandra Suryadevara; Robin G Bombardi; Robert H Carnahan; Alexander Bukreyev; Thomas W Geisbert; Andrew B Ward; James E Crowe
Journal:  Cell       Date:  2021-10-28       Impact factor: 41.582

5.  Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines.

Authors:  Linling He; Anshul Chaudhary; Xiaohe Lin; Cindy Sou; Tanwee Alkutkar; Sonu Kumar; Timothy Ngo; Ezra Kosviner; Gabriel Ozorowski; Robyn L Stanfield; Andrew B Ward; Ian A Wilson; Jiang Zhu
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

6.  Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.

Authors:  Nikolai Eroshenko; Taylor Gill; Marianna K Keaveney; George M Church; Jose M Trevejo; Hannu Rajaniemi
Journal:  Nat Biotechnol       Date:  2020-07       Impact factor: 54.908

Review 7.  Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus.

Authors:  Chean Yeah Yong; Hui Kian Ong; Swee Keong Yeap; Kok Lian Ho; Wen Siang Tan
Journal:  Front Microbiol       Date:  2019-08-02       Impact factor: 5.640

Review 8.  Susceptibility of the Elderly to SARS-CoV-2 Infection: ACE-2 Overexpression, Shedding, and Antibody-dependent Enhancement (ADE).

Authors:  Jean Pierre Schatzmann Peron; Helder Nakaya
Journal:  Clinics (Sao Paulo)       Date:  2020-05-15       Impact factor: 2.365

Review 9.  The signal pathways and treatment of cytokine storm in COVID-19.

Authors:  Lan Yang; Xueru Xie; Zikun Tu; Jinrong Fu; Damo Xu; Yufeng Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-07

Review 10.  Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.

Authors:  Hsin-I Shih; Chi-Jung Wu; Yi-Fang Tu; Chia-Yu Chi
Journal:  Biomed J       Date:  2020-05-30       Impact factor: 4.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.